Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib and SBRT in Oligo-metastatic EGFR-mutant NSCLC
NCT05167851Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yonsei University. Primary endpoint: Progression-Free Survival at 1 year. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05167851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167851.